From Motley Fool: Despite the ongoing political storm over U.S. prescription drug prices, major drug manufacturers -- or "Big Pharma" -- remain, on balance, an attractive group of equities for … [Read more...]

From The Street: Energy stocks have rebounded well off their lows as oil prices have recovered, but with investment strategists expecting higher oil prices in the years to come, energy stocks should … [Read more...]

From The Street: Corporate insiders sell their own companies' stock for a number of reasons. They might need the cash for a big personal purchase such as a new house, or they might need the cash to … [Read more...]

From Motley Fool: Creating entertainment that people actually want to watch in numbers that make it profitable has always been a bit of gamble. Sometimes artistic successes fail commercially, … [Read more...]

From Motley Fool: Although it's never a particularly good strategy to blindly follow other investors, the activity of elite investors like Carl Icahn and Warren Buffet (which is reported quarterly) … [Read more...]

From Investorplace: Contrary to popular belief, April isn’t a lethargic month for the market. Following on from what’s usually a bullish March, the S&P 500, on average, gains 1.2% for the month … [Read more...]

From Motley Fool: No cholesterol drug is likely to ever reach the sales level that Lipitor was able to achieve, but investors can still profit buying stock in companies developing drugs for … [Read more...]